Parexel sees modest quarterly growth as backlog rises by nearly $1bn

By Zachary Brennan contact

- Last updated on GMT

Parexel sees modest quarterly growth as backlog rises by nearly $1bn

Related tags: Von rickenbach, Revenue

Although Parexel’s consolidated service revenue increased by only 2% for the quarter, the company reported that its backlog included gross new business wins of $942.4m, which was 5.3% higher than the same quarter as last year.

CEO Josef von Rickenbach told investors Thursday: “We continue to be excited about the market opportunities that are in front of us, driven both by strategic partnerships and mid and small client companies, and we believe that we are well positioned to capitalize on them.”

Generally, von Rickenbach added, that the company saw “good RFP flow and bookings​,” though they were “tilted more to large companies and strategic partners – so far that seems to be the path in this calendar year​.”

On the more negative side, the company’s consulting segment experienced some client delays on a couple of large projects which negatively impacted quarterly revenue. The company also reported a slightly elevated level of cancellations of $289.7m, though von Rickenbach noted that they “were not performance-based​” and only related to two clients.

As far as employees added, von Rickenbach noted the “significant increases​” continue from the recent acquisition of Quantum Solutions India​, which will add 900 employees, and other GlaxoSmithKline employees​, which are “in anticipation of work moving through various stages of study startup and full production​.”

Analysts seemed lukewarm on the results and the stock price fell by about 7% Thursday. Still, Citi’s Garen Sarafian noted that the current quarter’s book to bill of 1.3 is the third highest over the last 11 quarters, and through the first three quarters of this FY, the company’s net book-to-bill is now 1.24, which is “well above its 1.14x average in Fiscal 2014 and particularly poor F1Q15’s 0.88x​.”

We expect that revenue growth in our Parexel Consulting business will be back on track in the fourth quarter on a sequential basis​,” von Rickenbach noted. “Revenue in our Clinical Research Services and Parexel Informatics businesses came in as we expected​.”

Moving forward, Parexel lowered its yearly revenue range expectations slightly, from $2.04 - $2.07bn to $2.012bn - $2.032bn.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us


View more